StocksMediumUpdated•Originally published 28 September 2026•Updated 28 September 2026•
1 min read
Merck Signs $2.13B Licensing Deal with China's SciBrunch for Cancer Treatment
Key Facts
1Merck signed a global licensing deal with China's SciBrunch Therapeutics to develop and sell an experimental cancer treatment.
2The total potential value of the deal is up to $2.13 billion, covering development, manufacturing, and sales rights.
Merck signed a global licensing deal with China's SciBrunch Therapeutics to develop and sell an experimental cancer treatment. Reuters reported that the total potential value of the agreement is approximately $2.13 billion. The deal covers development, manufacturing, and sales rights for the investigational therapy.
MRK closed at $148.74 on September 25, 2026, with the stock reaching a session high of $149.94 and a low of $147.48. The company intends to expand its oncology pipeline through this acquisition of rights from the Chinese biotech firm.
Latest Updates · 1
- Notable·
Update: The deal includes a $400 million upfront payment to SciBrunch for the SPR2015 candidate. This experimental drug is a preclinical oral KRAS G12D inhibitor.